Abstract
Even though hydrochlorothiazide (HCTZ) and chlorthalidone are frequently considered interchangeable antihypertensive agents, they appear to differ both in their blood pressure lowering efficacy and in their effects on the lipid profile and on serum potassium, uric acid and glucose levels. More importantly, in randomized controlled trials, chlorthalidone was equally or more effective than other antihypertensive agents in cardiovascular risk reduction whereas treatment with HCTZ yielded conflicting results. Although there are no randomized trials comparing the effects of these two agents on cardiovascular events, retrospective data from the Multiple Risk Factor Intervention Trial suggest that chlorthalidone might reduce cardiovascular morbidity more than HCTZ. However, current guidelines do not consistently recommend one or the other and it remains to be established which one is the diuretic of choice.
Keywords: Hydrochlorothiazide, chlorthalidone, hypertension, thiazide diuretics, cardiovascular disease.
Current Pharmaceutical Design
Title:Hydrochlorothiazide vs. Chlorthalidone as the Optimal Diuretic for the Management of Hypertension
Volume: 19 Issue: 21
Author(s): Konstantinos Tziomalos, Vassilios G. Athyros, Dimitri P. Mikhailidis and andAsterios Karagiannis
Affiliation:
Keywords: Hydrochlorothiazide, chlorthalidone, hypertension, thiazide diuretics, cardiovascular disease.
Abstract: Even though hydrochlorothiazide (HCTZ) and chlorthalidone are frequently considered interchangeable antihypertensive agents, they appear to differ both in their blood pressure lowering efficacy and in their effects on the lipid profile and on serum potassium, uric acid and glucose levels. More importantly, in randomized controlled trials, chlorthalidone was equally or more effective than other antihypertensive agents in cardiovascular risk reduction whereas treatment with HCTZ yielded conflicting results. Although there are no randomized trials comparing the effects of these two agents on cardiovascular events, retrospective data from the Multiple Risk Factor Intervention Trial suggest that chlorthalidone might reduce cardiovascular morbidity more than HCTZ. However, current guidelines do not consistently recommend one or the other and it remains to be established which one is the diuretic of choice.
Export Options
About this article
Cite this article as:
Tziomalos Konstantinos, G. Athyros Vassilios, P. Mikhailidis Dimitri and Karagiannis andAsterios, Hydrochlorothiazide vs. Chlorthalidone as the Optimal Diuretic for the Management of Hypertension, Current Pharmaceutical Design 2013; 19 (21) . https://dx.doi.org/ 10.2174/13816128113199990315
DOI https://dx.doi.org/ 10.2174/13816128113199990315 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Incidence of Adverse Drug Reactions in Patients Treated with Statins in the Emirates: A Retrospective Cohort Study
Current Vascular Pharmacology EDITORIAL (Thematic Issue: Preeclampsia and Modern Approaches to Diagnosis and Therapy)
Current Women`s Health Reviews The Potential of Statins for Individualized Colorectal Cancer Chemoprevention
Current Drug Targets Recent Advances in Small Molecule Inhibitors of VEGFR and EGFR Signaling Pathways
Current Topics in Medicinal Chemistry Development and Validation of a Sensitive HPLC-MS/MS-ESI Method for Determination of Febuxostat: Application to Pharmacokinetic Study
Current Analytical Chemistry Subject Index to Volume 2
Current Pharmacogenomics Aquaporins in Sensory and Pain Transmission
Current Neuropharmacology Role of the Transforming-Growth-Factor-β1 Gene in Late-Onset Alzheimer’s Disease: Implications for the Treatment
Current Genomics Ageing and Nutritional Therapy Adherence in Type 2 Diabetes
Current Diabetes Reviews Targeting JAK/STAT Signaling Pathway in Inflammatory Diseases
Current Signal Transduction Therapy Interrelationship Between Periapical Lesion and Systemic Metabolic Disorders
Current Pharmaceutical Design New Developments in the Diagnosis and Management of Resistant Hypertension
Current Medicinal Chemistry Ion Channel Architecture of the Renal Microcirculation
Current Hypertension Reviews Advanced Glycation: How are we Progressing to Combat this Web of Sugar Anomalies in Diabetic Nephropathy
Current Pharmaceutical Design Cardioprotection with Sildenafil: Implications for Clinical Practice
Current Medicinal Chemistry Dysregulation of LncRNAs in Placenta and Pathogenesis of Preeclampsia
Current Drug Targets Mechanisms of Action of Hypertonic Saline Resuscitation in Severe Sepsis and Septic Shock
Endocrine, Metabolic & Immune Disorders - Drug Targets Toxics of Tobacco Smoke and Cardiovascular System: From Functional to Cellular Damage
Current Pharmaceutical Design Repurposed Drugs as Potential Therapeutic Candidates for the Management of Alzheimer's Disease
Current Drug Metabolism Sedation in PACU: Indications, Monitoring, Complications
Current Drug Targets